{
  "pmcid": "3719169",
  "sha256": "49d346a64c5b70c94e8d3de4ebcd8dfc7ca4e01ceb920a6e32443234d79d1e09",
  "timestamp_utc": "2025-11-09T22:38:26.104203+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.135336448598135,
    "reading_ease": 34.285714953271054,
    "word_count": 214
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial on the Influence of EVD Laterality on Intraventricular Hemorrhage Clearance"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive either thrombolytic agents or placebo through the EVD."
      },
      "Participants": {
        "score": 1,
        "evidence": "100 patients from two CLEAR Phase II trials were assessed."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either thrombolytic agents or placebo through the EVD."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates whether EVD laterality affects blood clearance from the ventricular system, with and without thrombolytic agents."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the rate of IVH clearance over the first 3 days, measured by CT scans."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, with allocation concealment ensured by sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "100 patients from two CLEAR Phase II trials were assessed."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Thrombolytic administration significantly enhanced IVH clearance compared to placebo, irrespective of EVD laterality (p < 0.005, CI −14.0, −4.14 for contralateral and CI −24.7, −5.44 for ipsilateral EVD)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}